{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:43:40Z","timestamp":1759693420576,"version":"build-2065373602"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shanghai Association of the Integration of Traditional and Western Medicine","award":["SH201741"],"award-info":[{"award-number":["SH201741"]}]},{"name":"Independent Innovation of Health System Research","award":["ptkwws201708"],"award-info":[{"award-number":["ptkwws201708"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.109995","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T19:18:01Z","timestamp":1592075881000},"page":"109995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Intelligence quotient level and treatment of obsessive-compulsive disorders: Meta-analyses"],"prefix":"10.1016","volume":"144","author":[{"given":"Lidan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youguo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed E.A.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youguo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jocrd.2014.02.001","article-title":"Introduction: a global perspective on unwanted intrusive thoughts","volume":"3","author":"Clark","year":"2014","journal-title":"J Obsessive-Compul Relat Disord"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/da.20693","article-title":"Hoarding disorder: a new diagnosis for DSM-V?","volume":"27","author":"Mataix-Cols","year":"2010","journal-title":"Depress Anxiety"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive\u2013compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depress Anxiety"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.22259","article-title":"DSM-5 obsessive-compulsive and related disorders: Clinical implications of new criteria","volume":"31","author":"Van Ameringen","year":"2014","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.mehy.2020.109995_b0025","doi-asserted-by":"crossref","unstructured":"Mataix-Cols, D., A. Pertusa, and J.F. Leckman, Issues for DSM-V: how should obsessive-compulsive and related disorders be classified?, 2007, Am Psychiatric Assoc.","DOI":"10.1176\/appi.ajp.2007.07040568"},{"key":"10.1016\/j.mehy.2020.109995_b0030","first-page":"133","article-title":"Diagnostic and statistical manual of mental disorders","volume":"17","author":"Association","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.mehy.2020.109995_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cpr.2018.09.003","article-title":"The impact of symptom severity on cognitive function in obsessive-compulsive disorder: a meta-analysis","volume":"67","author":"Abramovitch","year":"2019","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/npy.11.22","article-title":"Assessment scales for obsessive-compulsive disorder","volume":"1","author":"Storch","year":"2011","journal-title":"Neuropsychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0045","first-page":"312","article-title":"Assessing obsessive-compulsive disorder (OCD): a review of self-report measures","volume":"1","author":"Overduin","year":"2012","journal-title":"J Obsess Compul Relat Disord"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The yale-brown obsessive compulsive scale: II Validity","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0055","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0060","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/16506070510043750","article-title":"Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder","volume":"34","author":"Cottraux","year":"2005","journal-title":"Cognit Behav Ther"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"15","key":"10.1016\/j.mehy.2020.109995_b0075","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mehy.2020.109995_b0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/COC.0000000000000388","article-title":"Obesity is independently associated with increased risk of hepatocellular cancer\u2013related mortality","volume":"41","author":"Gupta","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"7414","key":"10.1016\/j.mehy.2020.109995_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2020.109995_b0095","unstructured":"(RevMan), R.M., 2014."},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41398-018-0128-4","article-title":"Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline","volume":"8","author":"Lissemore","year":"2018","journal-title":"Transl Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0105","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1177\/0269881119878177","article-title":"Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: a placebo-controlled, randomized clinical trial","volume":"33","author":"Shalbafan","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","article-title":"Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study","volume":"34","author":"Rutrick","year":"2017","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.dcn.2018.11.004","article-title":"No evidence of differences in cognitive control in children with autism spectrum disorder or obsessive-compulsive disorder: an fMRI study","volume":"36","author":"Gooskens","year":"2019","journal-title":"Dev Cognit Neurosci"},{"key":"10.1016\/j.mehy.2020.109995_b0125","unstructured":"Kim, T., et al., Neural bases of the clinical and neurocognitive differences between early-and late-onset obsessive\u2013compulsive disorder. 2019."},{"key":"10.1016\/j.mehy.2020.109995_b0130","article-title":"Self-reported and neurocognitive impulsivity in obsessive-compulsive disorder","author":"Frydman","year":"2019","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0135","article-title":"Inhibition-related cortical hypoconnectivity as a candidate vulnerability marker for obsessive-compulsive disorder","author":"Hampshire","year":"2019","journal-title":"Biol Psychiatry Cognit Neurosci Neuroimag"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/00048670802050546","article-title":"Anterior cingulate glutamate\u2013glutamine levels predict symptom severity in women with obsessive\u2013compulsive disorder","volume":"42","author":"Y\u00fccel","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.2044-8260.1997.tb01227.x","article-title":"Autobiographical memory in obsessive-compulsive disorder","volume":"36","author":"Wilhelm","year":"1997","journal-title":"Br J Clin Psychol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/87565641.2013.839682","article-title":"Neurocognitive dysfunction and regional cerebral blood flow in medically naive patients with obsessive-compulsive disorder","volume":"39","author":"Wen","year":"2014","journal-title":"Dev Neuropsychol"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0155","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0005-7967(01)00095-X","article-title":"Thought suppression in obsessive-compulsive disorder","volume":"40","author":"Tolin","year":"2002","journal-title":"Behav Res Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jbtep.2013.04.001","article-title":"Ethical sensitivity in obsessive-compulsive disorder and generalized anxiety disorder: the role of reversal learning","volume":"44","author":"Szab\u00f3","year":"2013","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpsychires.2005.04.004","article-title":"Are there reliable neuropsychological deficits in obsessive\u2013compulsive disorder?","volume":"40","author":"Simpson","year":"2006","journal-title":"J Psychiatr Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1748-6653.2012.02035.x","article-title":"Impaired body but not face perception in patients with obsessive\u2013compulsive disorder","volume":"7","author":"Shin","year":"2013","journal-title":"J Neuropsychol"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0175","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1037\/a0018653","article-title":"Do organizational strategies mediate nonverbal memory impairment in drug-na\u00efve patients with obsessive-compulsive disorder?","volume":"24","author":"Shin","year":"2010","journal-title":"Neuropsychology"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0180","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.biopsych.2013.09.002","article-title":"The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder","volume":"75","author":"Shin","year":"2014","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0185","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1037\/0894-4105.18.4.665","article-title":"Deficits of organizational strategy and visual memory in obsessive-compulsive disorder","volume":"18","author":"Shin","year":"2004","journal-title":"Neuropsychology"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1139\/jpn.0955","article-title":"Reduced cortical folding of the anterior cingulate cortex in obsessive\u2013compulsive disorder","volume":"34","author":"Shim","year":"2009","journal-title":"J Psychiatry Neurosci JPN"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0195","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/hbm.22371","article-title":"Reduced functional connectivity within the limbic cortico-striato-thalamo-cortical loop in unmedicated adults with obsessive-compulsive disorder","volume":"35","author":"Posner","year":"2014","journal-title":"Hum Brain Mapp"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0200","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1017\/S0033291713002250","article-title":"Default network connectivity as a vulnerability marker for obsessive compulsive disorder","volume":"44","author":"Peng","year":"2014","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/JCP.0b013e3181c8b44f","article-title":"Amantadine augmentation for refractory obsessive-compulsive disorder: a case report","volume":"30","author":"Pasquini","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pscychresns.2009.05.002","article-title":"A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder","volume":"174","author":"Page","year":"2009","journal-title":"Psychiatry Res Neuroimag"},{"issue":"10","key":"10.1016\/j.mehy.2020.109995_b0215","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/hbm.21372","article-title":"Reduced fronto-callosal fiber integrity in unmedicated OCD patients: a diffusion tractography study","volume":"33","author":"Oh","year":"2012","journal-title":"Hum Brain Mapp"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0220","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jpsychires.2008.10.013","article-title":"Working memory dysfunction in obsessive\u2013compulsive disorder: a neuropsychological and functional MRI study","volume":"43","author":"Nakao","year":"2009","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.biopsych.2004.12.039","article-title":"Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study","volume":"57","author":"Nakao","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pscychresns.2007.11.001","article-title":"Functional MRI study of brain activation alterations in patients with obsessive\u2013compulsive disorder after symptom improvement","volume":"163","author":"Nabeyama","year":"2008","journal-title":"Psychiatry Res Neuroimag"},{"key":"10.1016\/j.mehy.2020.109995_b0235","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pnpbp.2012.09.002","article-title":"Differential neural network of checking versus washing symptoms in obsessive-compulsive disorder","volume":"40","author":"Murayama","year":"2013","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0240","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.biopsych.2013.02.004","article-title":"Altered activation in fronto-striatal circuits during sequential processing of conflict in unmedicated adults with obsessive-compulsive disorder","volume":"75","author":"Marsh","year":"2014","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1503\/jpn.110059","article-title":"Evidence for fractional anisotropy and mean diffusivity white matter abnormalities in the internal capsule and cingulum in patients with obsessive\u2013compulsive disorder","volume":"37","author":"Lochner","year":"2012","journal-title":"J Psychiatry Neurosci JPN"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0925-4927(02)00104-X","article-title":"Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive\u2013compulsive disorder","volume":"122","author":"Kwon","year":"2003","journal-title":"Psychiatry Res Neuroimag"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0255","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/arclin\/acq040","article-title":"Sensitivity and specificity of a digit symbol recognition trial in the identification of response bias","volume":"25","author":"Kim","year":"2010","journal-title":"Arch Clin Neuropsychol"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0260","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.pnpbp.2010.06.031","article-title":"A pilot study of brain activation in children with trichotillomania during a visual-tactile symptom provocation task: a functional magnetic resonance imaging study","volume":"34","author":"Lee","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/da.20195","article-title":"Electrophysiological correlates of behavioral response inhibition in patients with obsessive\u2013compulsive disorder","volume":"24","author":"Kim","year":"2007","journal-title":"Depress Anxiety"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0270","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1600-0447.2003.00087.x","article-title":"Anterior cingulotomy for refractory obsessive\u2013compulsive disorder","volume":"107","author":"Kim","year":"2003","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-3956(02)00017-1","article-title":"Neuropsychological profile in patients with obsessive-compulsive disorder over a period of 4-month treatment","volume":"36","author":"Kim","year":"2002","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.mehy.2020.109995_b0280","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pnpbp.2012.11.001","article-title":"Neural correlates of altered response inhibition and dysfunctional connectivity at rest in obsessive\u2013compulsive disorder","volume":"40","author":"Kang","year":"2013","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.nicl.2013.06.013","article-title":"Abnormal corticostriatal-limbic functional connectivity in obsessive\u2013compulsive disorder during reward processing and resting-state","volume":"3","author":"Jung","year":"2013","journal-title":"NeuroImage Clin"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0290","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-0447.2010.01659.x","article-title":"Aberrant ventral striatal responses during incentive processing in unmedicated patients with obsessive\u2013compulsive disorder","volume":"123","author":"Jung","year":"2011","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00406-008-0833-8","article-title":"BOLD response during visual perception of biological motion in obsessive-compulsive disorder","volume":"259","author":"Jung","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0300","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S1355617707070063","article-title":"Neuropsychological profiles of patients with obsessive-compulsive disorder: early onset versus late onset","volume":"13","author":"Hwang","year":"2007","journal-title":"J Int Neuropsychol Soc"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0004867411432851","article-title":"Clinical and neurocognitive profiles of subjects at high risk for psychosis with and without obsessive\u2013compulsive symptoms","volume":"46","author":"Hur","year":"2012","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/brain\/awm277","article-title":"Neural correlates of cognitive inflexibility during task-switching in obsessive-compulsive disorder","volume":"131","author":"Gu","year":"2007","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1503\/jpn.100082","article-title":"White matter microstructure in patients with obsessive\u2013compulsive disorder","volume":"36","author":"Bora","year":"2011","journal-title":"J Psychiatry Neurosci JPN"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0320","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/da.20171","article-title":"Morphometric alterations of anterior superior temporal cortex in obsessive\u2013compulsive disorder","volume":"23","author":"Choi","year":"2006","journal-title":"Depress Anxiety"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0325","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1002\/da.20377","article-title":"Nonverbal memory dysfunction in obsessive-compulsive disorder patients with checking compulsions","volume":"25","author":"Cha","year":"2008","journal-title":"Depress Anxiety"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0330","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/arclin\/acp052","article-title":"Executive functions and the obsessive-compulsive disorder: on the importance of subclinical symptoms and other concomitant factors","volume":"24","author":"B\u00e9dard","year":"2009","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11065-017-9358-0","article-title":"Meta-analysis of intelligence quotient (IQ) in obsessive-compulsive disorder","volume":"28","author":"Abramovitch","year":"2018","journal-title":"Neuropsychol Rev"},{"issue":"12","key":"10.1016\/j.mehy.2020.109995_b0340","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.brat.2004.11.012","article-title":"Treatment of obsessive\u2013compulsive disorder: cognitive behavior therapy vs. exposure and response prevention","volume":"43","author":"Whittal","year":"2005","journal-title":"Behav Res Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0345","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0005-7967(94)00052-L","article-title":"Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder","volume":"33","author":"Van Oppen","year":"1995","journal-title":"Behav Res Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0350","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive\u2013compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0355","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4088\/JCP.v67n0717","article-title":"A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder","volume":"67","author":"Sousa","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0360","unstructured":"Shareh, H., et al., Metacognitive therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with obsessive-compulsive disorder (OCD). 2010."},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0365","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-0447.2006.00767.x","article-title":"Cognitive behaviour therapy and medication in the treatment of obsessive\u2013compulsive disorder","volume":"113","author":"O'Connor","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0370","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hup.317","article-title":"Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine","volume":"16","author":"Mundo","year":"2001","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0375","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004714-199708000-00005","article-title":"Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study","volume":"17","author":"Mundo","year":"1997","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1037\/0022-006X.69.2.205","article-title":"Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder","volume":"69","author":"McLean","year":"2001","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0390","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004850-200511000-00003","article-title":"St John's wort versus placebo in obsessive\u2013compulsive disorder: results from a double-blind study","volume":"20","author":"Kobak","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0395","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10879-009-9110-z","article-title":"Satiation therapy and exposure response prevention in the treatment of obsessive compulsive disorder","volume":"39","author":"Khodarahimi","year":"2009","journal-title":"J Contem Psychother"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0400","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1440-1819.2004.01278.x","article-title":"Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients","volume":"58","author":"Kamijima","year":"2004","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.mehy.2020.109995_b0405","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2020.109995_b0410","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0415","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder","volume":"10","author":"Halaris","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0420","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/0022-006X.65.3.405","article-title":"Cognitive\u2014behavioral treatment of obsessive thoughts: a controlled study","volume":"65","author":"Freeston","year":"1997","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0430","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000056269","article-title":"A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder","volume":"70","author":"Cottraux","year":"2001","journal-title":"Psychother Psychosom"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000070785","article-title":"Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial","volume":"72","author":"Cordioli","year":"2003","journal-title":"Psychother Psychosom"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0445","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0924-9338(97)89646-0","article-title":"A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder","volume":"12","author":"Bisserbe","year":"1997","journal-title":"Eur Psychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0450","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-200204000-00007","article-title":"Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study","volume":"22","author":"Bergeron","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.janxdis.2011.08.008","article-title":"Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial","volume":"26","author":"Belotto-Silva","year":"2012","journal-title":"J Anxiety Disord"},{"issue":"10","key":"10.1016\/j.mehy.2020.109995_b0460","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1017\/S0033291712000244","article-title":"Internet-based cognitive behaviour therapy for obsessive\u2013compulsive disorder: a randomized controlled trial","volume":"42","author":"Andersson","year":"2012","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0465","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brat.2006.01.016","article-title":"Group versus individual cognitive-behavioural treatment for obsessive-compulsive disorder: a controlled trial","volume":"45","author":"Anderson","year":"2007","journal-title":"Behav Res Ther"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0470","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4088\/JCP.v63n1108","article-title":"Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study","volume":"63","author":"Albert","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.mehy.2020.109995_b0475","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0480","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Kordon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.mehy.2020.109995_b0485","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress Anxiety"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0490","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"31","author":"Muscatello","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0495","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0500","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor\u2013refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0505","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive\u2013compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0510","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","article-title":"Adding quetiapine to SRI in treatment-resistant obsessive\u2013compulsive disorder: a randomized controlled treatment study","volume":"20","author":"Fineberg","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0520","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2020.109995_b0525","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","author":"Denys","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-244X-5-5","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]","volume":"5","author":"Carey","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0535","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","author":"Bystritsky","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0540","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archpsyc.57.1.76","article-title":"Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders","volume":"57","author":"Hoehn-Saric","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0545","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1990.01810180077011","article-title":"Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine","volume":"47","author":"Goodman","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0550","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0924-977X(95)00071-V","article-title":"Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder","volume":"6","author":"Lopez-Ibor","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0555","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004850-199705000-00002","article-title":"A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder","volume":"12","author":"Milanfranchi","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0560","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199604000-00004","article-title":"Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison","volume":"16","author":"Koran","year":"1996","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0565","first-page":"301","article-title":"Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison","volume":"55","author":"Freeman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0570","unstructured":"Smeraldi, E., et al., Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: A preliminary study. New Trends in Experimental & Clinical Psychiatry, 1992."},{"key":"10.1016\/j.mehy.2020.109995_b0575","article-title":"A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder","author":"Pigott","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0580","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00004714-199904000-00013","article-title":"Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder","volume":"19","author":"Kronig","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0585","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0590","article-title":"Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo","author":"Jenike","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0595","article-title":"Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder","author":"Chouinard","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.mehy.2020.109995_b0600","article-title":"Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder","author":"Jenike","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0605","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0610","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial","volume":"11","author":"Goodman","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109995_b0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10401239209150443","article-title":"Short-and long-term treatment of obsessive-compulsive disorder with fluvoxamine","volume":"4","author":"Mallya","year":"1992","journal-title":"Ann Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2020.109995_b0625","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/ajp.147.9.1209","article-title":"A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory","volume":"147","author":"Jenike","year":"1990","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109995_b0630","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0635","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive\u2013compulsive disorder","volume":"169","author":"Zohar","year":"1996","journal-title":"Br J Psychiatry"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0640","first-page":"272","article-title":"Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine","volume":"54","author":"Hoehn-Saric","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0645","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-199008000-00005","article-title":"Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels","author":"Mavissakalian","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.mehy.2020.109995_b0650","article-title":"Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients","author":"Greist","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2020.109995_b0655","article-title":"Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients","author":"Jenike","year":"1989","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2020.109995_b0660","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","article-title":"Clomipramine in the treatment of patients with obsessive-compulsive disorder","volume":"48","author":"DeVeaugh-Geiss","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0665","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchemneu.2003.09.003","article-title":"The nucleus accumbens: a target for deep brain stimulation in obsessive\u2013compulsive-and anxiety-disorders","volume":"26","author":"Sturm","year":"2003","journal-title":"J Chem Neuroanat"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0670","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3171\/jns.2003.98.5.1104","article-title":"Treatment of patients with intractable obsessive\u2014compulsive disorder with anterior capsular stimulation: case report","volume":"98","author":"Anderson","year":"2003","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0675","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1227\/01.NEU.0000064565.49299.9A","article-title":"Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder","volume":"52","author":"Nuttin","year":"2003","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0680","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1034\/j.1600-0447.2003.00066.x","article-title":"Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases","volume":"107","author":"Gabri\u00ebls","year":"2003","journal-title":"Acta Psychiatr Scand"},{"issue":"9342","key":"10.1016\/j.mehy.2020.109995_b0685","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0140-6736(02)11339-0","article-title":"Compulsions, Parkinson's disease, and stimulation","volume":"360","author":"Mallet","year":"2002","journal-title":"Lancet"},{"issue":"9189","key":"10.1016\/j.mehy.2020.109995_b0690","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0140-6736(99)02376-4","article-title":"Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder","volume":"354","author":"Nuttin","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mehy.2020.109995_b0695","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3171\/jns.2004.100.6.1084","article-title":"Effect of subthalamic nucleus stimulation on obsessive\u2014compulsive disorder in a patient with Parkinson disease: Case report","volume":"100","author":"Fontaine","year":"2004","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.mehy.2020.109995_b0700","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3171\/jns.2004.101.4.0682","article-title":"Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive\u2014compulsive disorder and major depression: Case report","volume":"101","author":"Aouizerate","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.mehy.2020.109995_b0705","doi-asserted-by":"crossref","unstructured":"Aouizerate, B., et al., Deep brain stimulation for OCD and major depression. American Journal of Psychiatry, 2005. 162(11): p. 2192-2192.","DOI":"10.1176\/appi.ajp.162.11.2192"},{"issue":"5","key":"10.1016\/j.mehy.2020.109995_b0710","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2004.11.042","article-title":"Deep brain stimulation for refractory obsessive-compulsive disorder","volume":"57","author":"Abelson","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.mehy.2020.109995_b0715","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00415-006-0404-8","article-title":"Deep brain stimulation of the nucleus accumbens and the internal capsule in therapeutically refractory Tourette-syndrome","volume":"254","author":"Kuhn","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.mehy.2020.109995_b0720","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cpr.2015.10.001","article-title":"Remote cognitive\u2013behavior therapy for obsessive\u2013compulsive symptoms: a meta-analysis","volume":"43","author":"Wootton","year":"2016","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.mehy.2020.109995_b0725","doi-asserted-by":"crossref","unstructured":"Soomro, G.M., et al., Selective serotonin re\u2010uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane database of systematic reviews, 2008(1).","DOI":"10.1002\/14651858.CD001765.pub3"},{"issue":"Suppl. 10","key":"10.1016\/j.mehy.2020.109995_b0730","first-page":"9","article-title":"American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am J Psychiatry"},{"year":"2013","series-title":"Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder","author":"Koran","key":"10.1016\/j.mehy.2020.109995_b0735"},{"issue":"3","key":"10.1016\/j.mehy.2020.109995_b0740","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120037428","article-title":"Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose","volume":"42","author":"Isbister","year":"2004","journal-title":"J Toxicol Clin Toxicol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720312020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720312020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:24:58Z","timestamp":1759692298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720312020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":148,"alternative-id":["S0306987720312020"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109995","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intelligence quotient level and treatment of obsessive-compulsive disorders: Meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109995"}}